TARSUS PHARMACEUTICALS, INC. Derivative Liability, Noncurrent
TARSUS PHARMACEUTICALS, INC. (TARS) had Derivative Liability, Noncurrent of $48.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2023-03-17
- 2022-12-31: Derivative Liability, Noncurrent $48.00K.
- 2022-09-30: Derivative Liability, Noncurrent $40.00K.
- 2022-06-30: Derivative Liability, Noncurrent $43.00K.
- 2022-03-31: Derivative Liability, Noncurrent $71.00K.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2022-12-31 | $48.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $40.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $43.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $71.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $114.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $150.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $107.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $123.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |